---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-037601"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:35:39.247387+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Esperion Q2 revenue $82.4M (+12% Y/Y); first operating income of $15M; expects sustainable profitability Q1 2026

## Summary
- U.S. net product revenue $40.3M, +42% Y/Y; total prescriptions up 10% sequential.
- Net loss per share $0.02 vs $0.33 loss a year ago; operating income from ongoing business $15M.
- Reached settlements with three ANDA filers to block generic NEXLETOL until 2040.
- Royalty revenue from European partner up 30% sequentially to $13.6M; Japan approval on track for H2 2025.
- Reiterated FY2025 opex $215-235M; cash $86.1M; shares outstanding ~200.2M.

## SEC filing metadata
- accession: 0001628280-25-037601
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828025037601/0001628280-25-037601-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828025037601/espr-20250805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-037601
- JSON: https://secwatch.observer/filing/0001628280-25-037601.json
- Plain text: https://secwatch.observer/filing/0001628280-25-037601.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.